Previous 10 | Next 10 |
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug prod...
Recro Pharma, Inc. (REPH) Q4 2020 Earnings Conference Call February 26, 2021, 08:00 ET Company Participants Stephanie Diaz - IR David Enloe - President, CEO & Director Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Jacob Johnson - Stephens Inc. Presentation Operat...
The following slide deck was published by Recro Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Recro Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation
Gainers: Xtant Medical (XTNT) +189%.Intrusion (INTZ) +33%.Armstrong Flooring (AFI) +28%.Just Energy Group (JE) +28%.AMC Networks (AMCX) +26%.Applied UV (AUVI) +24%.Fisker (FSR) +21%.Ocugen (OCGN) +20%.Select Medical (SEM) +19%.Rubius Therapeutics (RUBY) +19%.Losers: Tricid...
Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%,...
Recro Pharma (REPH): Q4 GAAP EPS of -$0.48 misses by $0.22.Revenue of $9.91M (-43.8% Y/Y) misses by $5.09M.Press Release For further details see: Recro Pharma EPS misses by $0.22, misses on revenue
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook Strong Heading into 2021 Clinical Trials Support Services, L...
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug produ...
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug produ...
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug produ...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...